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ABSTRACT
The incidence of lower extremity artery disease (LEAD) has increased worldwide 
in the last decade. Its severity has been associated with increased morbidity and 
mortality. Atherosclerosis is believed as the main cause of LEAD. Monocytes and 
low-density lipoprotein (LDL) are the hallmarks of atherosclerosis. High-density 
lipoprotein (HDL) plays a role in suppressing the activation of monocytes. 
The monocyte to HDL ratio (MHR) has been reported as a marker of coronary 
artery disease complexity. However, this marker has not been investigated to 
assessthe LEAD severity. The study aimed to investigate the association between 
MHR and LEAD severity. This was an analytic observational study using a cross-
sectional design. Patients were selected from the Vascular Disease Registry in 
Dr.Sardjito General Hospital, Yogyakarta from January 2016 – January 2019. The 
blood sample was drawn at one day prior, on the day, or one day after duplex 
ultrasound performed. The duplex ultrasound was then interpreted based on 
the duplex ultrasound score. Patients were classified into two groups according 
to the score i.e. severe (score ≥ 8) and nonsevere (score< 8). Where as, the MHR 
was classified into two groups according to the cut-off point i.e. high (≥ 14.51) 
and low (< 14.51). The Chi-square test was used for statistical analysis and pvalue 
<0.05 was considered as statistically significant. A total of 50 patients were 
involved in this study. There were 21 (42%) patients in the severe group and 
29 (58%) in the nonsevere group. The proportion of the high MHR group and 
the low MHR group with severe levels of LEAD were 12 (57.1%) and 9 (42.9%), 
respectively. However, it was not statistically significant [p = 0.145; CI95% PR 
1.57 (0.81 – 3.03)]. In conclusion, there is no association between MHR and LEAD 
severity.
ABSTRAK
Insidensi penyakit arteri ekstremitas bawah (lower extremity artery disease /
LEAD) meningkat di seluruh dunia pada beberapa decade terakhir. Tingkat 
keparahannya dikaitkan dengan meningkatnya morbiditas dan mortalitas. 
Aterosklerosis diduga penyebab utama LEAD. Monosit dan lipoprotein densitas 
rendah (LDL) adalah penanda adanya aterosklerosis. Sedangkan lipoprotein 
densitas tinggi (HDL) berperan  penting menekan aktivasi monosit. Rasio monosit 
terhadap HDL (MHR) telah dilaporkan sebagai penanda kompleksitas penyakit 
arteri koroner. Namun demikian, apakah penanda ini dapat menggambarkan 
keparahan LEAD belum pernah dikaji. Penelitian ini bertujuan untuk mengkaji 
hubungan antara MHR dan keparahan LEAD. Penelitian ini merupakan 
penelitian observasi dengan rancangan potong lintang. Subjek penelitian 
diseleksi dari Register Penyakit Vaskular di RSUP Dr. Sardjito, Yogyakarta dari 
Januari 2016 - Januari 2019. Sampel darah diambil satu hari sebelum, pada 
saat dan sesudah duplex ultra sound dilakukan. Duplex ultra sound selanjutnya 
diinterpretasi berdasarkan skor duplex ultra sound. Subjek dikelompokan 
menjadi dua kelompok menurut skorya itu parah (nilai ≥ 8) dan ringan (nilai< 8). 
Sedangkan MHR dikelompokkan menjadi dua kelompok menurut nilai ambang 
batas yaitu tinggi (≥ 14,51) dan rendah (< 14,51). Uji Chi-square digunakan 
untuk analisis statistiknya dan nilai p< 0,05 dianggap berbeda secara nyata. 
Sebanyak 50 pasien dilibatkan dalam penelitian ini. Terdapat 21 (42%) pasien 
dalam kelompok parah dan 29 (58%) ringan. Proporsi kelompok MHR tinggi dan 
rendah dengan tingkat keparahan LEAD berturut-turut adalah 12 (57,1%) dan 9 
(42,9%). Namun demikian, hal ini tidak menunjukkan perbedaan nyata secara 
statistic [p = 0,145; CI95% PR 1,57 (0,81 – 3,03)]. Dapat disimpulkan, tidak ada 
hubungan antara MHR dan keparahan LEAD. 
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INTRODUCTION
Atherosclerosis is a chronic arterial 
disease characterized by inflammation 
and oxidation stress that results in the 
accumulation of lipids in the intima layer, 
lipid oxidation, foam cell formation, 
and plaque formation. Lower extremity 
artery disease (LEAD) is one of the main 
manifestations of atherosclerosis. The 
total number of individuals suffering 
from LEAD is increasing rapidly, with 
an increase of 23% in the last decade. 
Both symptomatic and asymptomatic, 
patients with LEAD have a high risk of 
experiencing cardio cerebrovascular 
events until death.1-7
Most LEAD could be detected with 
an ankle brachial index (ABI) ≤ 0.9 or 
a weakened pulse. Duplex ultrasound 
(DUS) is the first-line recommended 
imaging method to confirm LEAD. It 
is a noninvasive diagnostic modality 
that is easily accessible with relatively 
low costs. DUS was said to have 
sensitivity and specificity to detect 
lesions ≥ 50% (which were considered 
hemodynamically significant) at 88 and 
96 % when it was compared to digital 
subtraction angiography, computed 
tomography angiography (CTA) and 
magnetic resonance imaging (MRA).1,3,8 
Hiremath et al.9 created a DUS scoring 
system to assess the severity of LEAD. 
This DUS scoring system was used in 
this study to assess the severity of LEAD 
lesions.
The monocyte to high density 
lipoprotein ratio (MHR) has been 
extensively investigated to assess the 
severity of coronary artery disease.10,11 
However, until now, there has been no 
study of MHR in LEAD. MHR is based 
on the principle of the proinflammatory 
profile of monocytes in the chronic 
process of atherosclerosis and the 
antiinflammatory properties of high-
density lipoprotein (HDL). These 
laboratory parameters are widely 
accessible. The aim of this study was to 
determine the prevalence ratio between 
high MHR and the level of severity lesions 
of LEAD assessed based on DUS scores.
MATERIALS AND METHODS
Design and subjects
This was an observational 
analytic study using a cross-sectional 
design which carried out by taking of 
secondary data of DUS and laboratory 
examinataions nonrandomly from the 
Vascular Disease Registry in Dr. Sardjito 
General Hospital, Yogyakarta from 
January 2016 – January 2019. Tracking 
of the clinical data was performed 
through medical records. If the DUS 
and laboratory examination data were 
not taken according to a predetermined 
time, then DUS examination and the 
laboratory were repeated. During this 
period, there were 238 subjects. A total 
of 120 subjects were excluded. A total of 
118 subjects who fulfilled the inclusion 
and exclusion criteria were subjected 
to a sampling process. The DUS video 
of eighteen subjects was not found. 
The DUS video of 18 subjects was not 
readable, and 32 subjects were not 
subjected to laboratory tests when DUS 
was conducted. The estimated sample 
size was calculated using a comparison of 
two proportions formula and resulted 19 
subjects of the minimum sample size for 
each group. FIGURE 1 shows the number 
of subjects as many as 50 subjects who 
met the inclusion and exclusion criteria. 
This study was approved by the Medical 
and Health Research Ethics Committee, 
Faculty of Medicine-Public Health and 
Nursing, Universitas Gadjah Mada, 
Yogyakarta.
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 The lower extremity artery disease patients 
who were recorded in the registry of 
Vascular Disease at Dr. Sardjito general 
hospital(January 1, 2016 to January 2019) 
n = 238 
Subject 
n = 50 
Excluded: 
• Deaths (n = 31) 
• CKD on routine hemodialysis (n = 15) 
• Hematologic and nonhematologic 
malignancy (n = 14) 
• Autoimmune disease (n = 6) 
• Acute coronary syndrome (n = 7) 
• Acute limb ischaemia (n = 13) 
• Severe infection (n = 17) 
• Refused (n = 17) 
Subject that fulfills 
inclusion and exclusion criterian 
n = 118 
Sampling 
• Missing DUS video (n = 18) 
• Poor quality of DUS video (n = 18) 
• No laboratory data (n = 32) 
FIGURE 1.Recruitment flowchart of study subjects
Procedure
The independent variable was MHR, 
whereas the dependent variable was the 
severity of the lesion based on the DUS 
score. Confounding variables included 
age, gender, body mass index (BMI), 
ankle brachial index (ABI), diabetes 
mellitus, hypertension, smoking, drugs 
(statin groups, angiotensin converting 
enzyme inhibitors (ACEi)/angiotensin 
receptor blockers (ARB), calcium channel 
blockers (CCB)), monocyte count, and 
HDL.
MHR was divided into two groups 
based on the cutoff point of the receiver 
operating characteristics (ROC) curve. 
The first group was the high MHR ratio 
subjects with the ratio value of ≥ 14.51 
and the second group was low MHR 
ratio subjects with the ratio value of 
<14.51. Intraobserver reliability was also 
tested with Cohen’s Kappa by a trained 
sonographer who was blind to the MHR 
value.
Duplex ultrasound examination 
was performed using a machine (Philips 
1, Philips 2, GE Vivid 7) with a linear 
transducer 7 - 12 MHz.The examination 
started from the common femoral artery 
using B-mode, color Doppler, and pulse 
wave Doppler. The severity of the lesion 
was interpreted based on the DUS score. 
The component of the DUS score system 
is shown in TABLE 1, which consists of 
thickening of the intima (point 1). If there 
was a plaque, it was assessed whether 
the plaque causes stenosis. The amount 
of stenosis was measured by pulse or 
continuous wave Doppler examination 
in the intra- and proximal stenosis to 
obtain the PSV ratio value. If there was 
plaque, one of the criteria for plaque was 
chosen to determine whether there was 
no stenosis (point 1), stenosis less than 
50% (point 2) or stenosis more than 50% 
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(point 3). If there was thrombosis, the 
length of the thrombus was measured. If 
the thrombus size was less than half of 
the artery (point 1). If the thrombus was 
more than half of the artery (point 2). 
If stenosis or thrombosis was obtained, 
an assessment of collateral and distal 
flow must be assessed. If collateral and 
distal flow were absent, then each has 
2points. If collateral and distal flow were 
present, then each had1 point. The total 
maximum score was 10.9,12,13 
The severity level was classified into 
two groups: severe and nonsevere, as 
shown in TABLE 2.
TABLE 1. DUS scoring system of lower exremity artery diasease14
Severity level Positive DUS finding Present Absent
1 Intimo-medial thickening 1 0
2 Plaques not causing stenosis 1 0
3 Plaques causing <50% stenosis 2 0
4 Plaques causing >50% stenosis 3 0
5 Thrombosis of short segment 1 0
6 Thrombosis of long segment 2 0
In the presence of stenosis or thrombosis
7 Collaterals 1 2
8 Distal flow 1 2
Note:
Intimo-medial thickening: 1-2 mm; plaque: > 2 mm; stenosis: 
turbulensi in colour; stenosis < 50%: peak systolic velocity ratio < 2; 
Stenosis > 50%: peak systolic velocity ratio ≥ 2; short segment: < half 
of the artery. long segment: > half of the artery. The total maximum 
score was 10; DUS: duplex ultrasound.9, 12, 13
TABLE 2. Grading of the severity level 
of lower extremity artery 
disease based on DUS.
DUS Score Severity level
1 – 7 Nonsevere
8 -10 Severe
Note. DUS: duplex ultrasound
A blood sample examination was 
drawn on one day prior, on the day, or 
one day after the DUS examination.
These times of blood examination were 
based on the 20-40 hour availability of 
monocytes in circulation.15 MHR was 
calculated by dividing the monocyte 
count by the HDL count.
Statistical analysis
Hypothesis tests of the prevalence of 
MHR and lesion severity were carried out 
between 2 categorical variables using Chi 
square or Fisher’s exact test. Bivariate 
analysis was performed to determine 
confounding factors which influenced 
the severity of lesions. Stratification 
analysis was performed to control for 
confounding variables. A p value <0.05 
was considered statistically significant. 
Statistical analysis was performed using 
Statistical Package for Social Sciences 
(SPSS) version 21.0.
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RESULTS
The characteristics of the subjects 
are presented in TABLE 3. The age of 
the subjects ranged from 49 to 88 years 
with a mean of 66.92 ± 10.51 years, and 
the majority of subjects aged ≥ 50 years 
were 46 subjects (92%). Subjects were 
male and female, respectively, 25 (50%). 
The BMI range of subjects was 18.37 to 
32.42 kg/m2 with a median of 23.26 kg/
m2. The obesity category, namely, BMI ≥ 
25 kg/m2, includedas many as 14 subjects 
(28%). The median ABI value was 0.87 
(0.5 - 0.9), where as median score of DUS 
was 7 (5 - 8).
Risk factors in the subjects 
were diabetes mellitus in 40 (80%), 
hypertension in 42 (84%), and smoking 
in 13 (26%). The number of subjects 
who consumed routine treatment in the 
form of statins was 43 (86%), ACEi/ARB 
was 44 (88%), and CCB was 23 (46%). The 
number of subjects with criteria for lesion 
severity based on DUS examination were 
grouped into two groups, namely, severe 
and nonsevere, 21 (42%) and 29 (58%), 
respectively. 
TABLE 3. The characteristics of the study population
Variable n = 50
Age [years or n (%)]* 66.92 ± 10.51
•	 ≥ 50 46 (92)
•	 < 50 4 (8)
Sex[n (%)]
•	 Male 25 (50)
•	 Female 25 (50)
BMI [kg/m2orn (%)]** 23.26 (18.37 – 32.42)
•	 ≥ 25 14 (28)
•	 < 25 36 (72)
ABI** 0.87 (0.5 – 0.9)
Risk factors [n (%)]
•	 Diabetes mellitus 40 (80)
•	 Hipertension 42 (84)
•	 Smoker 23 (46)
Medication [n (%)]
•	 Statin 43 (86)
•	 ACEi/ARB 44 (88)
•	 CCB 23 (46)
Severity level [n (%)]
•	 Severe 21 (42)
•	 Nonsevere 29 (58)
DUS Score** 7 (5 – 8)
Monocyte count (/μL)** 530 (270 – 1340)
HDL (mg/dL)* 39.1 ± 10.73
MHR [rasio or n (%)] 14.51
•	 High 23 (46)
•	 Low 27 (54)
Note:
LEAD: lower extremity artery disease; DUS: duplex ultrasound; 
BMI: body mass index, ABI: ankle brachial index; ACEi: angiotensin 
converting enzyme inhibitors; ARB: angiotensin receptor blockers; 
CCB: calcium channel blockers; HDL: high density lipoprotein; MHR: 
monosit-high density lipoproteinratio; *Data are given as the mean 
and standard deviation; **Data are given as median and persentile
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The MHR was categorized into two 
groups, high and low,based on the cut-
off point of the ROC curve as shown in 
FIGURE 2 and was determined using the 
Youden index value. The area under the 
curve (AUC) on the ROC curve was 55.3% 
[p = 0.523; CI95% (38.8 – 71.9)]. The MHR 
cut-offpoint of 14.51 has a sensitivity 
and specificity of 57.1% and 62.1%, 
respectively, to predict the severe level 
of LEAD.
Hypothesis testing to determine 
the difference in the prevalence ratio 
between high and low MHR values to the 
severity level of LEAD was performed 
using a 2x2 table test with Chi Square test. 
Chi-square analysis, as shown in TABLE 
4, showed no difference in proportion 
between high MHR values compared to 
low MHR values for the occurrence of a 
severe level of LEAD [p = 0.145; CI95% 
1.57 (0.81 - 3.03)].
FIGURE 2. ROC curveof MHR to severity level of LEAD; AUC 55.3% 
[p = 0.523; CI95% (38.8 – 71.9)].
TABLE 4. Hypothetical test prevalence ratio between MHR and LEAD
Variable






(n = 29) Min Max
MHR value [n (%)]
•	 High 12 (57.1) 11 (37.9)
0.145 1.57 0.81 3.03
•	 Low 9 (42.9) 18 (62.1)
Note:
MHR: Monosit-high density lipoprotein ratio; LEAD: lower extremity artery 
disease; PR: prevalence ratio, CI: confidence interval
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Bivariate analysis was performed 
to determine the relationship between 
confounding factors and the severity 
of lesions. The results of the bivariate 
analysis are shown in TABLE 5. The 
bivariate test results found significant 
TABLE 5. Bivariate analysis of confounding factors to severity level of LEAD
Variable
Severity level of LEAD
p PR CI 95%(Min-Max)Severe (n = 21) Nonsevere(n = 29)
Sex [n (%)]
•	Male 9 (42.9) 16 (55.2)
0.284 0.75
0.39 - 1.46
•	Female 12 (57.1) 13 (44.8)
Age [years or n (%)]* 69.14± 10.98 65.31 ± 10.03 0.103 3.83(-2,18–9.85)
•	≥ 50 20 (95.2) 26 (89.7)
0.425 1.74
0.31- 9.80
•	< 50 1 (4.8) 3 (10.3)
BMI [kg/m2 or n(%)]** 22.76 (18.37-31.18) 26.41 (19.98–32.42) 0.301
•	≥ 25 5 (23.8) 9 (31)
0.404 0.80
0.36 - 1.77
•	< 25 16 (76.2) 20 (69)
ABI** 0.80 (0.5 - 0.9) 0.89 (0.76-0.9) 0.002
DM [n(%)]
•	Yes 17 (81) 23 (79.3)
0.589 1.06
0.46-2.46
•	No 4 (19) 6 (20.7)
Hipertension [n (%)]
•	Yes 17 (81) 25 (86.2)
0.451 0.81
0.37 - 1.77
•	Not 4 (19) 4 (13.8)
Smoker[n(%)]
•	Yes 6 (28.6) 7 (24.1)
0.490 1.14
0.56 - 2.30
•	Not 15 (71.4) 22 (75.9)
Statin [n (%)]
•	No 18 (85.7) 25 (86.2)
0.635 0.98
0.39 - 2.46
•	Yes 3 (14.3) 4 (13.8)
ACEi/ARB [n (%)]
•	No 18 (85.7) 26 (89.7)
0.499 0.82
0.34-1.96
•	Yes 3 (14.3) 3 (10.3)
CCB [n (%)]
•	No 9 (42.9) 14 (48.3)
0.464 0.88
0.45 - 1.71
•	Yes 12 (57.1) 15 (51.7)
Monocyte count (/μL)** 620(340-1340) 500 (270-770) 0.059
HDL(mg/dL)* 41.38 (13.27) 37.45 (8.29) 0.120 3.93(-2.76-10.62)
Note: LEAD: lower extremity artery disease; DUS: duplex ultrasound; BMI: body mass index, ABI: 
ankle brachial index;DM: diabetes mellitus; ACEi:angiotensin converting enzyme inhibitors; ARB: 
angiotensin receptor blockers; CCB: calcium channel blockers; CI: conficence interval; PR: prevalence 
rate; HDL: high density lipoprotein; *Data are given as the mean and standard deviation; **Data are 
given as median and persentile
differences between the ABI values and 
the incidence of severe degrees of lesions 
(p = 0.002). The median ABI values with 
severe and nonsevere lesions were 0.8 
(0.5 - 0.9) and 0.89 (0.76 - 0.9), respectively.
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DISCUSSION
The cut-off point of the MHR in 
this study was 14.51. This cut-off point 
devided the high MHR group ≥ 14.51 and 
low MHR <14.51. The number of subjects 
with high and low MHR was 23 (46%) 
and 27 (54%), respectively. The results of 
this study found a greater proportion of 
high MHR values than low MHR values 
for the occurrence of severe lesions, 
which amounted to 12 (57.1%) versus 
9 (42.9%). However, the difference in 
this proportion was not statistically 
significant [p=0.145; CI95% 1.57 (0.81 - 
3.03)].
Some factors might contribute to 
the results of this study. They included 
that the lesion severity score system 
used in this study was practically a novel 
scoring system, where further research 
is still needed. This study used this 
novel scoring system because there was 
no other severity assessment scoring 
system that also used DUS examination. 
DUS itself has several disadvantages, 
including its inability to describe the 
whole arteries, and the results obtained 
were often subjective depending on the 
operator. It also shows that the gold 
standard of LEAD lesion assessment still 
remains digital substration angiography 
or other imaging modalities such as 
magnetic resonance angiography or CT 
angiography.1,9
The value of monocytes in this study 
did not differ between groups of severe 
and nonsevere lesions (p=0.059). This 
was different from the study conducted 
by Wildgruber et al.16 where there was 
an increase in monocytes in the clinical 
severity of LEAD based on Rutherford 
criteria. However, a significant increase 
in the study did not explain whether 
the Rutherford III classification was 
accompanied by acute tissue loss, 
whereas this MHR study did not involve 
subjects with acute Rutherford III. It 
was also interesting to point out that 
intermediate monocytes (CD14++/CD16+) 
were the only monocytes that increased 
in severe peripheral arterial disease.16
Monocytes had 3 subpopulations 
in the form of (a) classical monocytes 
(CD14++/ CD16-), which were almost 
90% of all monocytes, and more 
proinflammatory CD16+, which 
were divided into (b) intermediate 
monocytes (CD14++/CD16+) and (c) 
nonclassical monocytes (CD14+/
CD16++). Intermediate monocytes 
(CD14++/CD16+) were said to have more 
proinflammatory properties because 
they produced reactive oxygen species 
(ROS), interleukin-1β (IL-1β) and tumor 
necrosis factor-α (TNF-α). Intermediate 
and nonclassical monocytes could even 
survive in circulation for 3-5 days.17
Monocytes are a type of leukocyte 
that play an important role in 
inflammation and atherosclerosis. 
Activated monocytes in endothelial 
cells trigger excessive expression of 
proinflammatory cytokines such as 
monocyte chemotactic protein-1 (MCP-
1), vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion 
molecule-1 (ICAM-1). Then, monocytes 
will differentiate into macrophages that 
engulf low-density lipoprotein (LDL) 
cholesterol to produce foam cells.18
HDL values in the group of severe 
and nonsevere lesions were not different 
(p = 0.120). The HDLmean value in the 
severe lesion group was even greater 
than that in the nonsevere lesion 
group, amounting to 41.38 (13.27) mg/
dL versus 37.45 (8.29) mg/dL. HDL has 
an anti-inflammatory effect on arteries 
through the inhibition of MCP-1, VCAM-
1 and ICAM-1 so that it could prevent 
the process of initiating atherosclerosis 
characterized by recruitment and 
infiltration of monocytes into the 
subendothelial layer.19 According to 
the density, HDL particles were divided 
into two main subclasses: low-density 
HDL2, which was rich in lipids, and high-
density HDL3, which was rich in protein. 
These two subclasses were divided into 
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three by size: (a) small HDL (7.3–8.2 
nm) including HDL3c and HDL3b, (b) 
moderate HDL (8.2–8.8 nm) including 
HDL3a, and (c) large HDL (8.8–13.0 
nm) including HDL2a and HDL2b.20 In 
a clinical study, it was said that small 
HDL had a positive correlation with the 
presence and severity and progression 
of atherosclerotic disease, in contrast 
to large HDL.21 The HDL study in LEAD 
by Kasko et al.22 showed that there is 
an HDL subfraction, namely, HDL3, 
which increased in LEAD. HDL3 is 
easily subjected to behavioral changes 
and is actually atherogenic in certain 
conditions, such as diabetes mellitus.
The average age of the subjects in 
this study was 69.92 ± 10.5 years with 
the majority of subjects aged  s easily 
subjected to behavioral changes and is 
actually atherogenic in Aboyans et al.1 
that LEAD occurs at the age of> 50 years. 
The relationship between increasing age 
and sex in the occurrence of LEAD is the 
same as that mentioned by Savji et al. in 
a study involving more than 3.6 million 
subjects aged urrence of23 Sex differences 
in the incidence of LEAD are still debated. 
Lower extremity artery disease tends to 
be difficult to recognize in women due to 
the asymptomatic majority.24,25 The male 
and female sex in this study were the 
same. It was in accordance with the ESC 
guidelines that risk factors that had been 
shown to be strongly related to LEAD 
were age, dyslipidemia, hypertension, 
diabetes mellitus, and smoking. Other 
risk factors, including gender, are still 
being studied. In this study, age and sex 
did not show differences in high and 
low group MHR values or in the severity 
level of group lesions. Other risk factors 
assessed in this study were as much as 
42 (84%) hypertension, 40 (80%) diabetes 
mellitus, 14 (28%) obesity and 13 (26%) 
smoking. These risk factors did not show 
significant differences in high and low 
group MHR or in the severity level of 
group lesions.
The ABI value showed a statistically 
significant difference in the severity of 
LEAD lesions (p=0.002). The median ABI 
values with severe and nonsevere lesions 
were 0.8 (0.5 - 0.9) and 0.89 (0.76 - 0.9), 
respectively. ABI is the first screening 
modality and diagnosis of LEAD. ABI 
≤0.9 has a sensitivity and specificity of 
75% and 86%, respectively, to establish a 
diagnosis of LEAD.1
Medical history in the form of statin, 
ACEi/ARB, and CCB drugs was the same 
between the two groups of severe and 
not severe lesions with each p = 0.635; 
p = 0.499; and p = 0.464. These drugs 
were commonly used to treat the risk 
factors of LEAD recommended by the 
ESC guidelines.1 These drugs were not 
different between the high- and low-MHR 
groups.
This study has several limitations, 
including the design of a cross-sectional 
study where monocytes and HDL 
samples were taken at one moment 
while the atherosclerotic process was a 
chronic process.
The assessment of the severity of 
the lesion using a DUS examination 
has disadvantages in describing the 
whole arterial system in the body. The 
DUS scoring system used in this study 
was a novel scoring system to assess 
the severity of LEAD. This DUS scoring 
system had never been studied to 
compare its accuracy in detecting lesions 
with the gold standard method, i.e., the 
DUS scoring system. digital substration 
angiography or other imaging modalities, 
such as magnetic resonance angiography 
or CT angiography, to assess the severity 
of LEAD. This DUS scoring system might 
need to be modified based on further 
research.
This study neither carried out HDL3, 
an HDL subfraction examination that 
easily underwent behavioral changes 
to be proaterogenic nor intermediate 
monocytes (CD14 ++/CD16+), the only 
subclass of monocytes that increased in 
severe peripheral arterial disease based 
on a previous study.
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CONCLUSION
There is no association between 
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